
Invivyd (IVVD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
11.8M
Gross Profit
11.1M
94.19%
Operating Income
-15.1M
-127.78%
Net Income
-14.7M
-124.38%
EPS (Diluted)
$-0.12
Balance Sheet Metrics
Total Assets
103.7M
Total Liabilities
49.6M
Shareholders Equity
54.1M
Debt to Equity
0.92
Cash Flow Metrics
Operating Cash Flow
-12.5M
Free Cash Flow
-21.3M
Revenue & Profitability Trend
Invivyd Income Statement From 2021 to 2024
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Revenue | 25.4M | 0 | 0 | 0 |
Cost of Goods Sold | 1.6M | - | - | - |
Gross Profit | 23.8M | - | - | - |
Gross Margin % | 93.6% | 0.0% | 0.0% | 0.0% |
Operating Expenses | ||||
Research & Development | 137.3M | 158.7M | 179.2M | 182.9M |
Selling, General & Administrative | 63.4M | 49.1M | 47.0M | 36.5M |
Other Operating Expenses | - | - | - | - |
Total Operating Expenses | 200.6M | 207.8M | 226.3M | 219.4M |
Operating Income | -176.9M | -207.8M | -226.3M | -219.4M |
Operating Margin % | -696.8% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | ||||
Interest Income | - | - | - | - |
Interest Expense | - | - | - | - |
Other Non-Operating Income | 7.0M | 9.1M | -15.1M | -7.4M |
Pre-tax Income | -169.9M | -198.6M | -241.3M | -226.8M |
Income Tax | - | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -169.9M | -198.6M | -241.3M | -226.8M |
Net Margin % | -669.4% | 0.0% | 0.0% | 0.0% |
Key Metrics | ||||
EBITDA | -173.8M | -200.8M | -204.0M | -211.9M |
EPS (Basic) | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
EPS (Diluted) | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
Basic Shares Outstanding | 118555073 | 109526053 | 108268289 | 42621265 |
Diluted Shares Outstanding | 118555073 | 109526053 | 108268289 | 42621265 |
Income Statement Trend
Invivyd Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 69.3M | 200.6M | 92.1M | 542.2M | 115.0M |
Short-term Investments | - | 0 | 279.9M | 49.2M | 0 |
Accounts Receivable | 10.9M | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | - | - | - | - | 141.0K |
Total Current Assets | 100.7M | 224.9M | 376.9M | 616.7M | 117.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.9M | 4.1M | 6.1M | 83.0K | - |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 25.9M | 175.0K | 191.0K | 3.3M | - |
Total Non-Current Assets | 28.8M | 4.3M | 6.2M | 3.4M | 0 |
Total Assets | 129.5M | 229.2M | 383.2M | 620.1M | 117.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 10.4M | 8.0M | 1.5M | 5.8M | 8.2M |
Short-term Debt | 1.3M | 1.4M | 1.6M | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 27.0K | 35.0K | 44.0K | - | - |
Total Current Liabilities | 62.0M | 50.3M | 25.0M | 62.1M | 13.1M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 722.0K | 2.2M | 0 | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | 700.0K | 1.0K | 12.0K | 11.0K |
Total Non-Current Liabilities | 0 | 1.4M | 2.2M | 12.0K | 169.6M |
Total Liabilities | 62.0M | 51.7M | 27.2M | 62.1M | 182.6M |
Equity | |||||
Common Stock | 12.0K | 11.0K | 11.0K | 11.0K | 1.0K |
Retained Earnings | -902.0M | -732.1M | -533.4M | -292.1M | -65.3M |
Treasury Stock | 0 | 0 | 0 | 0 | 85.0K |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 67.5M | 177.5M | 356.0M | 558.0M | -65.2M |
Key Metrics | |||||
Total Debt | 1.3M | 2.2M | 3.7M | 0 | 0 |
Working Capital | 38.7M | 174.6M | 351.9M | 554.7M | 104.3M |
Balance Sheet Composition
Invivyd Cash Flow Statement From 2021 to 2024
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | -169.9M | -198.6M | -241.3M | -226.8M |
Depreciation & Amortization | 3.1M | 2.0M | 462.0K | 1.0K |
Stock-Based Compensation | 19.8M | 18.7M | 21.6M | 17.8M |
Working Capital Changes | -35.6M | 5.6M | -1.6M | -5.7M |
Operating Cash Flow | -182.6M | -172.3M | -220.8M | -214.6M |
Investing Activities | ||||
Capital Expenditures | -140.0K | -615.0K | -1.7M | -84.0K |
Acquisitions | - | - | - | - |
Investment Purchases | 0 | -91.2M | -298.0M | -188.6M |
Investment Sales | 0 | 372.5M | 69.0M | 138.0M |
Investing Cash Flow | -140.0K | 280.7M | -230.7M | -50.7M |
Financing Activities | ||||
Share Repurchases | 0 | -1.0K | -4.0K | 0 |
Dividends Paid | - | - | - | - |
Debt Issuance | - | - | - | - |
Debt Repayment | - | - | - | - |
Financing Cash Flow | 38.7M | -150.0K | -4.0K | 662.7M |
Free Cash Flow | -170.6M | -173.8M | -221.7M | -184.8M |
Net Change in Cash | -144.1M | 108.2M | -451.5M | 397.3M |
Cash Flow Trend
Invivyd Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.80
Forward P/E
-5.70
Price to Book
3.20
Price to Sales
5.17
PEG Ratio
0.01
Profitability Ratios
Profit Margin
-238.33%
Operating Margin
-127.78%
Return on Equity
-120.08%
Return on Assets
-53.25%
Financial Health
Current Ratio
1.33
Debt to Equity
6.93
Beta
0.55
Per Share Data
EPS (TTM)
$-0.92
Book Value per Share
$0.36
Revenue per Share
$0.39
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ivvd | 238.7M | -0.80 | 3.20 | -120.08% | -238.33% | 6.93 |
Vertex | 101.6B | 28.19 | 5.91 | 22.77% | 31.86% | 8.89 |
Regeneron | 60.8B | 14.45 | 1.99 | 15.34% | 31.37% | 9.04 |
Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Tonix | 241.9M | 0.01 | 1.19 | -77.51% | 23.07% | 0.29 |
Annexon | 238.5M | -2.15 | 1.20 | -66.75% | 0.00% | 13.88 |
Financial data is updated regularly. All figures are in the company's reporting currency.